JP2008509955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509955A5 JP2008509955A5 JP2007526371A JP2007526371A JP2008509955A5 JP 2008509955 A5 JP2008509955 A5 JP 2008509955A5 JP 2007526371 A JP2007526371 A JP 2007526371A JP 2007526371 A JP2007526371 A JP 2007526371A JP 2008509955 A5 JP2008509955 A5 JP 2008509955A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- tetrahydro
- cyclobutyl
- benzazepin
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- -1 cyano, amino Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- OZVJGCNGTOCMDY-UHFFFAOYSA-N 1-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-methylimidazole-4-carboxamide Chemical compound C1=NC(C(=O)NC)=CN1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 OZVJGCNGTOCMDY-UHFFFAOYSA-N 0.000 claims 1
- LYCGOHZEXHRSEG-UHFFFAOYSA-N 1-[4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(C=C1)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 LYCGOHZEXHRSEG-UHFFFAOYSA-N 0.000 claims 1
- YQZIMSVEJPTIIF-UHFFFAOYSA-N 1-[4-[(3-cyclopentyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(C=C1)=CC=C1CC1=CC=C(CCN(CC2)C3CCCC3)C2=C1 YQZIMSVEJPTIIF-UHFFFAOYSA-N 0.000 claims 1
- NSJBQUKUADYKOX-UHFFFAOYSA-N 1-[5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazin-2-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(N=C1)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 NSJBQUKUADYKOX-UHFFFAOYSA-N 0.000 claims 1
- HCTIOBOUIVYAGI-UHFFFAOYSA-N 1-[5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-2-yl]-3-methylimidazolidin-2-one Chemical compound O=C1N(C)CCN1C(N=C1)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 HCTIOBOUIVYAGI-UHFFFAOYSA-N 0.000 claims 1
- OVYFOEMMKCCEMC-UHFFFAOYSA-N 1-[5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-2-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(N=C1)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 OVYFOEMMKCCEMC-UHFFFAOYSA-N 0.000 claims 1
- HAVWYPZNIYDKOG-UHFFFAOYSA-N 1-[5-[(3-cyclopentyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-2-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(N=C1)=CC=C1CC1=CC=C(CCN(CC2)C3CCCC3)C2=C1 HAVWYPZNIYDKOG-UHFFFAOYSA-N 0.000 claims 1
- XUJOWYHFLDSWBM-UHFFFAOYSA-N 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-3-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(C=N1)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 XUJOWYHFLDSWBM-UHFFFAOYSA-N 0.000 claims 1
- MWKDMLMOHSLISU-UHFFFAOYSA-N 3-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-methylimidazole-4-carboxamide Chemical compound CNC(=O)C1=CN=CN1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 MWKDMLMOHSLISU-UHFFFAOYSA-N 0.000 claims 1
- DRFASFBKVNYHCH-UHFFFAOYSA-N 3-[4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]-2h-1,2,4-oxadiazol-5-one Chemical compound N1OC(=O)N=C1C(C=C1)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 DRFASFBKVNYHCH-UHFFFAOYSA-N 0.000 claims 1
- UHOYFUZUSCIXIR-UHFFFAOYSA-N 3-[5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1C(N=C1)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 UHOYFUZUSCIXIR-UHFFFAOYSA-N 0.000 claims 1
- GMIGMRISMPGWON-UHFFFAOYSA-N 3-cyclobutyl-7-(pyrazin-2-ylmethyl)-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C=1N=CC=NC=1CC(C=C1CC2)=CC=C1CCN2C1CCC1 GMIGMRISMPGWON-UHFFFAOYSA-N 0.000 claims 1
- BJKVWBLBHOPOPV-UHFFFAOYSA-N 3-cyclobutyl-7-[(4-pyrazol-1-ylphenyl)methyl]-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C=1C=C2CCN(C3CCC3)CCC2=CC=1CC(C=C1)=CC=C1N1C=CC=N1 BJKVWBLBHOPOPV-UHFFFAOYSA-N 0.000 claims 1
- VWRAFRMDDHKIEP-UHFFFAOYSA-N 3-cyclobutyl-7-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C=1C=C2CCN(C3CCC3)CCC2=CC=1CC(C=C1)=CC=C1N1C=NC=N1 VWRAFRMDDHKIEP-UHFFFAOYSA-N 0.000 claims 1
- VUXUBNIGSMDJBP-UHFFFAOYSA-N 4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 VUXUBNIGSMDJBP-UHFFFAOYSA-N 0.000 claims 1
- DUIUKCKAGDAJPY-UHFFFAOYSA-N 4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 DUIUKCKAGDAJPY-UHFFFAOYSA-N 0.000 claims 1
- AIQNRPGDHDIKTK-UHFFFAOYSA-N 4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 AIQNRPGDHDIKTK-UHFFFAOYSA-N 0.000 claims 1
- PUXLLBMFGVBZQP-UHFFFAOYSA-N 4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 PUXLLBMFGVBZQP-UHFFFAOYSA-N 0.000 claims 1
- USTNOVQFGOFMTA-UHFFFAOYSA-N 4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 USTNOVQFGOFMTA-UHFFFAOYSA-N 0.000 claims 1
- TVAKYGOSGKIYQR-UHFFFAOYSA-N 4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 TVAKYGOSGKIYQR-UHFFFAOYSA-N 0.000 claims 1
- CYPHJRCYACZFJL-UHFFFAOYSA-N 4-[4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]thiadiazole Chemical compound C=1C=C2CCN(C3CCC3)CCC2=CC=1CC(C=C1)=CC=C1C1=CSN=N1 CYPHJRCYACZFJL-UHFFFAOYSA-N 0.000 claims 1
- FYUBPMWGGAMNGJ-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methoxy]-n-methylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CN=C1OCC1=CC=C(CCN(CC2)C3CCC3)C2=C1 FYUBPMWGGAMNGJ-UHFFFAOYSA-N 0.000 claims 1
- ZXVRCYJEMOYKEA-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n,n-dimethylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)N(C)C)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 ZXVRCYJEMOYKEA-UHFFFAOYSA-N 0.000 claims 1
- SMLYDZAHCUEOEF-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-(2,2,2-trifluoroethyl)pyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NCC(F)(F)F)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 SMLYDZAHCUEOEF-UHFFFAOYSA-N 0.000 claims 1
- QUJAQIXONOSQML-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-(oxan-4-yl)pyridine-2-carboxamide Chemical compound C=1C=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)C=NC=1C(=O)NC1CCOCC1 QUJAQIXONOSQML-UHFFFAOYSA-N 0.000 claims 1
- WYTGMSYLGSQVRL-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-methylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 WYTGMSYLGSQVRL-UHFFFAOYSA-N 0.000 claims 1
- MAGYJUUFQCTFGG-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 MAGYJUUFQCTFGG-UHFFFAOYSA-N 0.000 claims 1
- VVPXNXYWURAXRV-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-propan-2-ylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC(C)C)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 VVPXNXYWURAXRV-UHFFFAOYSA-N 0.000 claims 1
- AMPPEJGVVFMNSO-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-propan-2-ylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC(C)C)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 AMPPEJGVVFMNSO-UHFFFAOYSA-N 0.000 claims 1
- GGWPNQXOPSTPDZ-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 GGWPNQXOPSTPDZ-UHFFFAOYSA-N 0.000 claims 1
- MRXSBHAOCMBNKP-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 MRXSBHAOCMBNKP-UHFFFAOYSA-N 0.000 claims 1
- MKSSXOVDQMSLAG-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 MKSSXOVDQMSLAG-UHFFFAOYSA-N 0.000 claims 1
- GGFWKXWSICGNEB-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 GGFWKXWSICGNEB-UHFFFAOYSA-N 0.000 claims 1
- XKEGECUDELZRMU-UHFFFAOYSA-N 5-[(3-cyclopentyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methoxy]-n-methylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CN=C1OCC1=CC=C(CCN(CC2)C3CCCC3)C2=C1 XKEGECUDELZRMU-UHFFFAOYSA-N 0.000 claims 1
- DAGDBFMXJNBYTN-UHFFFAOYSA-N 5-[(3-cyclopentyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-methylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CN=C1CC1=CC=C(CCN(CC2)C3CCCC3)C2=C1 DAGDBFMXJNBYTN-UHFFFAOYSA-N 0.000 claims 1
- ZPMWFZGSLGAICJ-UHFFFAOYSA-N 5-[4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=CC(CC=3C=C4CCN(CCC4=CC=3)C3CCC3)=CC=2)=N1 ZPMWFZGSLGAICJ-UHFFFAOYSA-N 0.000 claims 1
- FQGOZSLBGMBCJC-UHFFFAOYSA-N 5-[5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazin-2-yl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2N=CC(CC=3C=C4CCN(CCC4=CC=3)C3CCC3)=NC=2)=N1 FQGOZSLBGMBCJC-UHFFFAOYSA-N 0.000 claims 1
- SWRCTQGLYZLFGD-UHFFFAOYSA-N 5-[5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-2-yl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2N=CC(CC=3C=C4CCN(CCC4=CC=3)C3CCC3)=CC=2)=N1 SWRCTQGLYZLFGD-UHFFFAOYSA-N 0.000 claims 1
- GSEANIAQOPZRDB-UHFFFAOYSA-N 5-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-3-yl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=NC(CC=3C=C4CCN(CCC4=CC=3)C3CCC3)=CC=2)=N1 GSEANIAQOPZRDB-UHFFFAOYSA-N 0.000 claims 1
- UDJPVVXXHFVKBZ-UHFFFAOYSA-N 6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methoxy]-n-methylpyridazine-3-carboxamide Chemical compound N1=NC(C(=O)NC)=CC=C1OCC1=CC=C(CCN(CC2)C3CCC3)C2=C1 UDJPVVXXHFVKBZ-UHFFFAOYSA-N 0.000 claims 1
- ABVFLGMOGPBRQR-UHFFFAOYSA-N 6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methoxy]-n-methylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1OCC1=CC=C(CCN(CC2)C3CCC3)C2=C1 ABVFLGMOGPBRQR-UHFFFAOYSA-N 0.000 claims 1
- NTXLDMWMZCHZLJ-UHFFFAOYSA-N 6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-n-methylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 NTXLDMWMZCHZLJ-UHFFFAOYSA-N 0.000 claims 1
- VDNXDJHYMQPAHK-UHFFFAOYSA-N 6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridine-3-carbonitrile Chemical compound N1=CC(C#N)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 VDNXDJHYMQPAHK-UHFFFAOYSA-N 0.000 claims 1
- QMKGVANSKAQRNJ-UHFFFAOYSA-N 6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)N)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 QMKGVANSKAQRNJ-UHFFFAOYSA-N 0.000 claims 1
- QIDSSWVUMTZYQM-UHFFFAOYSA-N 6-[(3-cyclopentyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methoxy]-n-methylpyridazine-3-carboxamide Chemical compound N1=NC(C(=O)NC)=CC=C1OCC1=CC=C(CCN(CC2)C3CCCC3)C2=C1 QIDSSWVUMTZYQM-UHFFFAOYSA-N 0.000 claims 1
- FDRABQXESINLQL-UHFFFAOYSA-N 6-[(3-cyclopentyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methoxy]-n-methylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1OCC1=CC=C(CCN(CC2)C3CCCC3)C2=C1 FDRABQXESINLQL-UHFFFAOYSA-N 0.000 claims 1
- WDNDBAZKABPSKR-UHFFFAOYSA-N 7-[(5-bromopyridin-2-yl)methyl]-3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound N1=CC(Br)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 WDNDBAZKABPSKR-UHFFFAOYSA-N 0.000 claims 1
- ICYLXHGEIRUWSR-UHFFFAOYSA-N 7-[(6-bromopyridin-3-yl)methyl]-3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C1=NC(Br)=CC=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 ICYLXHGEIRUWSR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- NKEHVZDOPKIKDJ-UHFFFAOYSA-N [4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)C=CC=1C(=O)N1CCOCC1 NKEHVZDOPKIKDJ-UHFFFAOYSA-N 0.000 claims 1
- XVXQKGMSQPOHEZ-UHFFFAOYSA-N [4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]-piperidin-1-ylmethanone Chemical compound C=1C=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)C=CC=1C(=O)N1CCCCC1 XVXQKGMSQPOHEZ-UHFFFAOYSA-N 0.000 claims 1
- KFNISZNONWEFKF-UHFFFAOYSA-N [4-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]phenyl]-pyrrolidin-1-ylmethanone Chemical compound C=1C=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)C=CC=1C(=O)N1CCCC1 KFNISZNONWEFKF-UHFFFAOYSA-N 0.000 claims 1
- BJITZALZDGZTSN-UHFFFAOYSA-N [5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazin-2-yl]-pyrrolidin-1-ylmethanone Chemical compound C=1N=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)C=NC=1C(=O)N1CCCC1 BJITZALZDGZTSN-UHFFFAOYSA-N 0.000 claims 1
- UJPSFYAPGWAQQR-UHFFFAOYSA-N [5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-2-yl]-pyrrolidin-1-ylmethanone Chemical compound C=1C=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)C=NC=1C(=O)N1CCCC1 UJPSFYAPGWAQQR-UHFFFAOYSA-N 0.000 claims 1
- KYBYTZZTQSZJBH-UHFFFAOYSA-N [6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound C=1C=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)N=CC=1C(=O)N1CCCC1 KYBYTZZTQSZJBH-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000000911 decarboxylating effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DPTPSTVVCHAKGB-UHFFFAOYSA-N n-(4-cyanophenyl)-5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyridine-2-carboxamide Chemical compound C=1C=C(CC=2C=C3CCN(CCC3=CC=2)C2CCC2)C=NC=1C(=O)NC1=CC=C(C#N)C=C1 DPTPSTVVCHAKGB-UHFFFAOYSA-N 0.000 claims 1
- JRXHVZVRUJVHMO-UHFFFAOYSA-N n-(cyanomethyl)-5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazine-2-carboxamide Chemical compound C1=NC(C(NCC#N)=O)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 JRXHVZVRUJVHMO-UHFFFAOYSA-N 0.000 claims 1
- DRIXLHFDXKXDAX-UHFFFAOYSA-N n-[5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazin-2-yl]acetamide Chemical compound C1=NC(NC(=O)C)=CN=C1CC1=CC=C(CCN(CC2)C3CCC3)C2=C1 DRIXLHFDXKXDAX-UHFFFAOYSA-N 0.000 claims 1
- ZATFGWIKFWNBSZ-UHFFFAOYSA-N n-methyl-6-[[3-(2-methylpropyl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]pyridazine-3-carboxamide Chemical compound N1=NC(C(=O)NC)=CC=C1OCC1=CC=C(CCN(CC(C)C)CC2)C2=C1 ZATFGWIKFWNBSZ-UHFFFAOYSA-N 0.000 claims 1
- PBXDMLVXWMFFLZ-UHFFFAOYSA-N n-methyl-6-[[3-(2-methylpropyl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1OCC1=CC=C(CCN(CC(C)C)CC2)C2=C1 PBXDMLVXWMFFLZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0418267.1A GB0418267D0 (en) | 2004-08-16 | 2004-08-16 | Novel compounds |
| PCT/EP2005/008841 WO2006018260A1 (en) | 2004-08-16 | 2005-08-12 | Tetrahydrobenzazepines as antagonists and/or reverse agonists of the histamine h 3 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509955A JP2008509955A (ja) | 2008-04-03 |
| JP2008509955A5 true JP2008509955A5 (OSRAM) | 2008-10-02 |
Family
ID=33017592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007526371A Pending JP2008509955A (ja) | 2004-08-16 | 2005-08-12 | ヒスタミンｈ３受容体のアンタゴニストおよび／または逆アゴニストとしてのテトラヒドロベンズアゼピン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070208005A1 (OSRAM) |
| EP (1) | EP1778643A1 (OSRAM) |
| JP (1) | JP2008509955A (OSRAM) |
| AR (1) | AR050698A1 (OSRAM) |
| GB (1) | GB0418267D0 (OSRAM) |
| PE (1) | PE20060625A1 (OSRAM) |
| TW (1) | TW200621716A (OSRAM) |
| WO (1) | WO2006018260A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540148A (en) | 2002-12-20 | 2007-11-30 | Glaxo Group Ltd | Benzazepine derivatives for the treatment of neurological disorders |
| GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
| CN101426373A (zh) | 2006-03-10 | 2009-05-06 | 神经原公司 | 哌嗪基氧代烷基四氢异喹啉及相关类似物 |
| WO2007149728A2 (en) * | 2006-06-20 | 2007-12-27 | Alcon Research, Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| KR20090024811A (ko) | 2006-06-23 | 2009-03-09 | 아보트 러보러터리즈 | 히스타민 ｈ3 수용체 조절제로서의 사이클로프로필 아민 유도체 |
| CL2008000596A1 (es) * | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
| CL2008000597A1 (es) * | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
| AU2008262664A1 (en) * | 2007-06-11 | 2008-12-18 | Valletta Health Ip Ee B.V. | Urocanic acid derivatives useful for the treatment of immune-related and inflammatory diseases |
| WO2009029632A1 (en) | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
| CA2731196A1 (en) * | 2008-07-18 | 2010-01-21 | Takeda Pharmaceuticals Company Limited | Benzazepine derivatives and their use as hstamine h3 antagonists |
| US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| EP2427458B1 (en) * | 2009-05-05 | 2014-05-07 | F.Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
| JP2013505297A (ja) * | 2009-09-21 | 2013-02-14 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ５の正のアロステリック調節因子としてのＯ−ベンジルニコチンアミド類似体 |
| WO2011083314A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
| WO2011083315A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Compounds and their use |
| WO2011083316A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| CN104016919A (zh) * | 2014-06-18 | 2014-09-03 | 安徽省逸欣铭医药科技有限公司 | 一种绿卡色林类似物及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060089347A1 (en) * | 2002-08-20 | 2006-04-27 | Eli Lilly And Company | Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses |
| NZ540148A (en) * | 2002-12-20 | 2007-11-30 | Glaxo Group Ltd | Benzazepine derivatives for the treatment of neurological disorders |
| WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| EP1694334B1 (en) * | 2003-12-18 | 2011-10-19 | Abbott GmbH & Co. KG | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
| US20050137186A1 (en) * | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| GB0405628D0 (en) * | 2004-03-12 | 2004-04-21 | Glaxo Group Ltd | Novel compounds |
-
2004
- 2004-08-16 GB GBGB0418267.1A patent/GB0418267D0/en not_active Ceased
-
2005
- 2005-08-12 US US11/573,732 patent/US20070208005A1/en not_active Abandoned
- 2005-08-12 JP JP2007526371A patent/JP2008509955A/ja active Pending
- 2005-08-12 WO PCT/EP2005/008841 patent/WO2006018260A1/en not_active Ceased
- 2005-08-12 EP EP05771678A patent/EP1778643A1/en not_active Withdrawn
- 2005-08-12 PE PE2005000939A patent/PE20060625A1/es not_active Application Discontinuation
- 2005-08-15 TW TW094127666A patent/TW200621716A/zh unknown
- 2005-08-16 AR ARP050103435A patent/AR050698A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509955A5 (OSRAM) | ||
| TWI797186B (zh) | 整合應激路徑之調節劑 | |
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP7001682B2 (ja) | 置換１Ｈ－イミダゾ［４，５－ｂ］ピリジン－２（３Ｈ）－オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用 | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| JP6964576B2 (ja) | 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 | |
| JP5444365B2 (ja) | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 | |
| JP2024059874A (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| JP7580136B2 (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| JP2024534526A (ja) | ピリジン系誘導体及びその使用 | |
| JP2019523233A (ja) | ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 | |
| JP2011522865A (ja) | Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物 | |
| JP2014525444A5 (OSRAM) | ||
| CN107207489A (zh) | 作为nadph氧化酶抑制剂的酰氨基噻二唑衍生物 | |
| TW201217362A (en) | Heteroaryls and uses thereof | |
| AU2017217931B2 (en) | Halo-substituted piperidines as orexin receptor modulators | |
| BR112015022474B1 (pt) | Compostos de piridina e pirazina substituídos como inibidores de pde4 | |
| RU2011149637A (ru) | Феноксиметильные гетероциклические соединения | |
| JP2006507247A5 (OSRAM) | ||
| JP5713511B2 (ja) | ロイコトリエン産生のオキサジアゾール阻害剤 | |
| JP2024543207A (ja) | 新規ｈｄａｃ阻害剤及びその治療的使用 | |
| CN103764145A (zh) | 作为治疗剂的异噁唑啉类化合物 | |
| JP4403305B2 (ja) | １，３−ベンゾチアジノン誘導体および用途 | |
| CN103781765A (zh) | 作为hdl-胆固醇升高剂的3-吡啶甲酰肼类 | |
| RU2833870C2 (ru) | СОЕДИНЕНИЯ 2,3-ДИГИДРОХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NaV1.8 |